CoChat

Epigenetic reversal of acquired resistance to 5-fluorouracil treatment

Humeniuk, Rita, Mishra, Prasun J., Bertino, Joseph R., Banerjee, Debabrata · 2009 · Molecular Cancer Therapeutics

Published version of a preprint

The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.

Abstract

Acquired and intrinsic resistance still remains a limitation to the clinical use of 5-fluorouracil (5-FU). The contribution of epigenetic changes to the development of drug resistance remains to be elucidated. Several genes that are hypermethylated and silenced have been identified in colorectal cancer. Based on the findings described in the accompanying article, we hypothesized that acquired resistance to “pulse” 5-FU has an epigenetic origin and might be reversed. Here, we present a novel therapeutic approach to circumvent clinical resistance to bolus 5-FU, that is, treatment of bolus 5-FU-resistant colorectal cancer cells with low-dose 5-azadeoxycytidine (DAC), an inhibitor of DNA hypermethylation, restored sensitivity to 5-FU as well as 5-fluorouridine. Moreover, treatment of nude mice bearing a 5-FU-resistant tumor, characterized by decreased levels of UMP kinase (UMPK), with DAC overcame resistance to bolus 5-FU. DAC-mediated restoration of 5-FU sensitivity was associated with increases in UMPK levels. An increase in UMPK protein and mRNA levels following treatment with low-dose DAC was observed in cultured bolus 5-FU-resistant colorectal cancer cells (HCT-8) and in mice bearing these tumors. We conclude that DAC-mediated restoration of sensitivity to bolus 5-FU is mediated at least in part by increased UMPK levels and clinical resistance to 5-FU due to decreased UMPK in colorectal cancer may be overcome by including methylation inhibitors such as DAC. [Mol Cancer Ther 2009;8(5):1045–54]

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-08-0717

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Cited by

See all 32

Metadata

Authors
Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D.
Affiliations
  • Rutgers Cancer Institute (US)
  • National Institutes of Health (US)
Venue
Molecular Cancer Therapeutics
Published
2009-05-01
Volume
8
Issue
5
Pages
1045-1054
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2117321270
Cited by
28
References
47
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 2 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 2 · 2013: 2 · 2012: 2
FWCI
1.00
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • Rutgers University Community Repository (Rutgers University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
5-fluorouracil resistance, epigenetic drug resistance, DNA methylation inhibitors, UMP kinase, colorectal cancer, acquired drug resistance, 5-fluorouridine, HCT-8 cells
MeSH terms
Decitabine, Animals, Antimetabolites, Antineoplastic, Azacitidine, Base Sequence, Fluorouracil, Humans, Mice, Nude, Molecular Sequence Data, Nucleoside-Phosphate Kinase, Promoter Regions, Genetic, Uridine, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, CpG Islands, Drug Resistance, Neoplasm, DNA Methylation, RNA Stability, Xenograft Model Antitumor Assays, Gene Order, Cell Line, Tumor, Mice, Epigenomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0717
The paper
Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D. (2009). Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0717

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.